Literature DB >> 30217929

Whole-Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naïve, High-Risk Prostate Cancer.

Weerachai Jaratlerdsiri1, Eva K F Chan1,2, Tingting Gong1,3, Desiree C Petersen1,2, Anton M F Kalsbeek1,2, Philip A Venter4, Phillip D Stricker5, M S Riana Bornman6, Vanessa M Hayes7,2,3,4,6.   

Abstract

: African-American men are more likely than any other racial group to die from prostate cancer. The contribution of acquired genomic variation to this racial disparity is largely unknown, as genomic from Africa is lacking. Here, we performed the first tumor-normal paired deep whole-genome sequencing for Africa. A direct study-matched comparison between African- and European-derived, treatment-naïve, high-risk prostate tumors for 15 cases allowed for further comparative analyses of existing data. Excluding a single hypermutated tumor with 55 mutations per megabase, we observed a 1.8-fold increase in small somatic variants in African- versus European-derived tumors (P = 1.02e-04), rising to 4-fold when compared with published tumor-matched data. Furthermore, we observed an increase in oncogenic driver mutations in African tumors (P = 2.92e-03); roughly 30% of impacted genes were novel to prostate cancer, and 79% of recurrent driver mutations appeared early in tumorigenesis. Although complex genomic rearrangements were less frequent in African tumors, we describe a uniquely hyperduplicated tumor affecting 149 transposable elements. Comparable with African Americans, ERG fusions and PIK3CA mutations were absent and PTEN loss less frequent. CCND1 and MYC were frequently gained, with somatic copy-number changes more likely to occur late in tumorigenesis. In addition to traditional prostate cancer gene pathways, genes regulating calcium ion-ATPase signal transduction were disrupted in African tumors. Although preliminary, our results suggest that further validation and investigation into the potential implications for elevated tumor mutational burden and tumor-initiating mutations in clinically unfavorable prostate cancer can improve patient outcomes in Africa. SIGNIFICANCE: The first whole-genome sequencing study for high-risk prostate cancer in African men allows a simultaneous comparison of ethnic differences relative to European populations and of the influences of the environment relative to African-American men. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/78/24/6736/F1.large.jpg.See related commentary by Huang, p. 6726. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2018        PMID: 30217929     DOI: 10.1158/0008-5472.CAN-18-0254

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

Review 1.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

Review 2.  An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines.

Authors:  Julie Dutil; Zhihua Chen; Alvaro N Monteiro; Jamie K Teer; Steven A Eschrich
Journal:  Cancer Res       Date:  2019-03-20       Impact factor: 12.701

3.  Psychosocial Stress, Glucocorticoid Signaling, and Prostate Cancer Health Disparities in African American Men.

Authors:  Leanne Woods-Burnham; Laura Stiel; Shannalee R Martinez; Evelyn S Sanchez-Hernandez; Herbert C Ruckle; Frankis G Almaguel; Mariana C Stern; Lisa R Roberts; David R Williams; Susanne Montgomery; Carlos A Casiano
Journal:  Cancer Health Disparities       Date:  2020

Review 4.  Race and prostate cancer: genomic landscape.

Authors:  Camilo Arenas-Gallo; Jude Owiredu; Ilon Weinstein; Patrick Lewicki; Spyridon P Basourakos; Randy Vince; Bashir Al Hussein Al Awamlh; Fredrick R Schumacher; Daniel E Spratt; Christopher E Barbieri; Jonathan E Shoag
Journal:  Nat Rev Urol       Date:  2022-08-09       Impact factor: 16.430

5.  CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer.

Authors:  Scott A Tomlins; Edward M Schaeffer; Tamara L Lotan; Farzana A Faisal; Sanjana Murali; Harsimar Kaur; Thiago Vidotto; Liana B Guedes; Daniela Correia Salles; Vishal Kothari; Jeffrey J Tosoian; Sumin Han; Daniel H Hovelson; Kevin Hu; Daniel E Spratt; Alexander S Baras
Journal:  Clin Cancer Res       Date:  2020-01-22       Impact factor: 12.531

Review 6.  Aging of the progenitor cells that initiate prostate cancer.

Authors:  Jack Freeland; Preston D Crowell; Jenna M Giafaglione; Paul C Boutros; Andrew S Goldstein
Journal:  Cancer Lett       Date:  2021-05-28       Impact factor: 8.679

7.  Metagenomic analysis reveals a rich bacterial content in high-risk prostate tumors from African men.

Authors:  Ye Feng; Weerachai Jaratlerdsiri; Sean M Patrick; Ruth J Lyons; Anne-Maree Haynes; Colin C Collins; Phillip D Stricker; M S Riana Bornman; Vanessa M Hayes
Journal:  Prostate       Date:  2019-08-27       Impact factor: 4.104

8.  Copy Number Profiles of Prostate Cancer in Men of Middle Eastern Ancestry.

Authors:  Alia Albawardi; Julie Livingstone; Saeeda Almarzooqi; Nallasivam Palanisamy; Kathleen E Houlahan; Aktham Adnan Ahmad Awwad; Ramy A Abdelsalam; Paul C Boutros; Tarek A Bismar
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

9.  Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.

Authors:  Oliver Sartor; Andrew J Armstrong; Chiledum Ahaghotu; David G McLeod; Matthew R Cooperberg; David F Penson; Philip W Kantoff; Nicholas J Vogelzang; Arif Hussain; Christopher M Pieczonka; Neal D Shore; David I Quinn; Eric J Small; Elisabeth I Heath; Ronald F Tutrone; Paul F Schellhammer; Matthew Harmon; Nancy N Chang; Nadeem A Sheikh; Bruce Brown; Stephen J Freedland; Celestia S Higano
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-02-28       Impact factor: 5.554

10.  Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.

Authors:  Mengli Guo; Zhen Chen; Yayi Li; Sijin Li; Fei Shen; Xiaoxiong Gan; Jianhua Feng; Wensong Cai; Qingzhi Liu; Bo Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-23       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.